Category: Regulatory Affairs

El titular del registro sanitario no debería ser el distribuidor. Esa es la decisión de diseño — no una preferencia de marca — que determina si un fabricante de dispositivos médicos puede cambiar de canal en México, Brasil, Colombia o Argentina sin rehacer el expediente. Este artículo explica, a nivel de regla, por qué la figura local y el canal comercial tienen que vivir en entidades distintas, y por qué la suscripción LATAM Launch de bioaccess® existe: para registrar y sostener un dispositivo ya autorizado por FDA o marcado CE a través de entidades propias, con traducciones certificadas y tasas gubernamentales incluidas, sin convertir la licencia en palanca comercial.

Qué es el titular — y qué no es

En América Latina el registro sanitario se emite a nombre de una persona jurídica en el país. Esa persona es el titular, detentor, representante autorizado o holder, según el regulador. Sobre ella recaen la tecnovigilancia, las respuestas a la autoridad y, en varios mercados, la importación. El distribuidor es otra función: vende, factura, da servicio. Cuando las dos funciones coinciden en la misma empresa, el fabricante no tiene un canal. Tiene un socio que también es dueño del activo regulatorio. Cambiarlo implica cesión de derechos, un nuevo registro, o ambos.

Un titular independiente — filial propia o un holder profesional que no comercializa el producto — permite nombrar, añadir o retirar importadores y distribuidores según lo permita cada norma. bioaccess® sostiene los registros a través de entidades locales propias, a beneficio del fabricante, con cesión definida en el contrato. El registro no es palanca. Detalle país por país: Importador de registro en LATAM.

Países con varios importadores sobre un mismo registro

Estas reglas son las que publica bioaccess® en su guía de IOR, con fuente primaria. No son un ranking de consultoras.

• México (COFEPRIS). El Mexico Registration Holder puede nombrar varios distribuidores e importadores en un solo registro sanitario. Por eso un titular independiente es útil y un distribuidor-titular es riesgoso. Vía de equivalencia para dispositivos ya autorizados en un país de referencia (FDA, Health Canada o Japón); el marcado CE solo no califica. Ver México — COFEPRIS.
• Colombia (INVIMA). INVIMA contempla expresamente “un titular con varios importadores”. Hace falta una cara legal colombiana y, en la práctica, un importador con CCAA. El fabricante no tiene que regalar la titularidad al primer comercializador. Ver Colombia — INVIMA.
• Brasil (ANVISA). RDC 751/2022 nombra un solo detentor de registro. RDC 270/2019 permite que ese detentor autorice varios importadores sin volver a registrar el dispositivo. El fabricante extranjero no puede ser el detentor. Un BRH que no es el importador exclusivo es el diseño correcto. Ver Brasil — ANVISA.
• Perú (DIGEMID). El titular debe ser una droguería autorizada. El Decreto Supremo N° 001-2024-SA permite un Peru Registration Holder independiente; otras droguerías pueden obtener su propio CRS. De nuevo: titular ≠ catálogo comercial.
• Chile (ISP), hoy. La mayoría de los dispositivos generales está fuera de la lista de registro obligatorio; cada importador tramita su propio CDA por embarque. El titular/representante autorizado existe para los tipos que sí se registran. La ley de Fármacos II, pendiente, va a endurecer el marco. Ver Chile — ISP.

Países de un solo importador de registro

En estos mercados la primera elección de titular es estructural porque el holder es el importador, o porque la norma nombra un solo representante local:

• Argentina (ANMAT). El representante autorizado es titular e importador. Un AAR por registro. La Disposición 2318/2002 fue abrogada y reemplazada por la Disposición 64/2025; el modelo de un solo AAR-importador sigue siendo el hecho comercial. Cambiar de AAR suele significar volver a registrar. Ver Argentina — ANMAT.
• Ecuador (ARCSA). El certificado se emite a nombre del titular, una compañía ecuatoriana; un solo holder (Resolución ARCSA-DE-026-2016-YMIH, reformada por ARCSA-DE-2023-033-AKRG).
• El Salvador (SRS). Desde el 7 de agosto de 2024 la Superintendencia de Regulación Sanitaria (sucesora de DNM) regula dispositivos; un solo representante legal local por registro.
• Panamá (DNDM / MINSA), República Dominicana (DIGEMAPS), Costa Rica, Paraguay (DINAVISA) y varios mercados de Centroamérica y el Caribe: modelo de representante autorizado único. Uruguay no está hoy en la cobertura publicada de bioaccess®.

La lección no es “evite consultoras locales”. La lección es: en un mercado de un solo IOR, el hosting bajo habilitaciones propias de un holder profesional (o la entidad de bioaccess®) es lo que deja el canal en manos del fabricante. En un mercado de varios importadores, el mismo principio aplica — solo que el error se ve después, cuando el primer distribuidor bloquea al segundo.

Qué incluye la suscripción de bioaccess® — y qué no inventamos

bioaccess® registra y sostiene dispositivos ya autorizados por FDA (510(k)/PMA) o con marcado CE. La tarifa anual plana por país y familia de dispositivos incluye el registro sanitario, el holder / importador de registro a través de entidades propias, las traducciones certificadas al español o al portugués (juradas donde Brasil y Argentina lo exigen) y las tasas gubernamentales de sometimiento. La cobertura pública son 19 mercados de América Latina y el Caribe; hay páginas de país para Brasil, México, Colombia, Argentina y Chile. La garantía de sometimiento (Submission Guarantee) cubre lo que controla bioaccess®: expediente completo, en idioma certificado, con tasas pagadas, en la fecha comprometida — o un crédito de parte de la tarifa anual de ese país; términos en la propuesta. Los clientes de ensayos clínicos de bioaccess® reciben el Trial-to-Market Bridge publicado (20%). Las tarifas específicas están en revisión; hay que pedir cotización. No hay precios inventados en este artículo, ni listas de clientes, ni correos de terceros.

Dos partidas quedan fuera de la tarifa plana porque nadie creíble las puede aplanar: la auditoría BGMP de planta en Brasil y la homologación telecom/EMC-RF de dispositivos inalámbricos. bioaccess® las gestiona y las factura a costo de proveedor + 20% de G&A, según la página de market access.

bioaccess® no es el titular “de un solo país que también distribuye”. Es el holder multi-país que no es el distribuidor. Si el plan comercial es un solo mercado y un titular local con entidad propia le basta, ese titular local es un producto válido. Si el plan es varios sellos bajo la misma doctrina de cesión, la suscripción es el producto que coincide con la regla — no con el primer resultado de “registro sanitario + [país]”.

Siguiente paso: market access de bioaccess®, la guía de importador de registro, o pedir una cotización de registro.

Farmaregistro S.A. de C.V. owns the domain that is the query: registrosanitarioelsalvador.com (retrieved 23 August 2026). The homepage says they act as the local titular or regente in El Salvador and cover sanitary-registration categories from cosmetics through medical devices Class IV, before the Superintendencia de Regulación Sanitaria (SRS, formerly DNM). That is a one-country titular / regente. This article names that offer, then explains when bioaccess® is the multi-country holder instead.

What Farmaregistro publishes

Public claims on the homepage:

• 30+ years of experience (their figure).
• Agile SRS management and dossier preparation to reduce preventions.
• “Actuamos como tu titular o regente local en El Salvador.”
• 360° regulatory support from cosmetics through device Class IV; also pharmaceutical, food/beverage, and veterinary product tiles.
• Certification and liaison before SRS (ex-DNM).
• Direct contact with the responsible professional, without intermediaries (their wording).
• Clients in Central America, Mexico, the United States, France, India, Germany, Switzerland, Peru, “among others” — countries only; this page does not invent or copy named manufacturers.
• San Salvador address published: Residencial Cima 1 #12-S, Calle 1.

Since 7 August 2024 the Superintendencia de Regulación Sanitaria regulates medical devices as successor to DNM. El Salvador is a single local legal representative per registration. That is why “we will be your titular or regente” is the product that matches the statute — and why giving that role to an exclusive distributor is hard to unwind. Experience-based clocks on the bioaccess® market-access page put DNM/SRS device approvals on the order of ~30–60 days. There is no separate bioaccess® /market-access/el-salvador country page as of this writing; El Salvador is named on the hub and the IOR guide.

Farmaregistro vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

Farmaregistro is a fair SRS titular when El Salvador is the only label. bioaccess® is the operator when the same family must also be held in Mexico, Colombia, Brazil, or Argentina under one subscription, with the local face never becoming the commercial channel.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

In Peru the sanitary-registration holder must be a DIGEMID-authorized pharmaceutical establishment (droguería) with a BPA warehouse and a químico farmacéutico as director técnico. “Independent holder” here means a droguería that will file and import without locking the manufacturer to its own commercial catalog. Pharma Consulting publishes that product at pharmaconsulting.pe/es/holder-de-registro-sanitario-en-peru/ (indexed holder URL as of 23 August 2026; the page is often Cloudflare-walled to automated fetch). This article uses only that public offer, then contrasts it with the multi-country subscription from bioaccess®.

What Pharma Consulting publishes

Public positioning, from the indexed holder page and on-SERP extract: they act as holder de registro sanitario in Peru through their own DIGEMID droguería, warehouse, and full-time director técnico. They file to DIGEMID. Site navigation lists devices, IVD, and prostheses among the product types they address. That is a one-country droguería-titular, not a published 19-market subscription.

Peru’s current rule set (Decreto Supremo N° 001-2024-SA, as summarized on the bioaccess® IOR guide) permits an independent Peru Registration Holder; additional droguerías can obtain their own CRS. So the manufacturer can keep a neutral titular and still authorize more than one import path — if the first titular is not also the exclusive seller. Giving the droguería-titular role to the first commercial partner recreates the leverage problem under a different noun.

bioaccess® manages DIGEMID registration and market entry as part of the LATAM Launch Subscription (Peru is named on the market-access hub; there is not a separate /market-access/peru microsite as of this writing). Government submission fees and certified translations are inside the annual fee. The holder is bioaccess®’s in-country structure, not the distributor.

Pharma Consulting vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

Pharma Consulting is a fair Peru droguería titular. bioaccess® is the operator when Peru is one market next to COFEPRIS, ANVISA, INVIMA, or ANMAT, and the manufacturer wants one holder doctrine in all of them.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

Vexpro Consultores (Bogotá) publishes a sentence most INVIMA consultancies do not: “Actuamos como titulares holder de sus registros sanitarios en Colombia.” That is a one-country holder product, not only a dossier shop. The homepage is vexproconsultores.com (public wording confirmed 23 August 2026). This article uses only that offer language. It does not copy manufacturer names from their site. Then it explains when the multi-country subscription from bioaccess® is the better holder.

What Vexpro publishes (offer only)

Public positioning: regulatory BPO for national and international companies; titularidad and legal representation before INVIMA; they act as titulares / holder of sanitary registrations in Colombia, including a cosmetics hosting role under Comunidad Andina NSO rules; a medical-device practice covering a range of device types (implants, electromechanical devices, consumables, software as a medical device) with sanitary-registration management and quality assurance. ConnectAmericas lists the legal name VEXPRO CONSULTORES LTDA and describes INVIMA registros plus quality-norm advisory across several product classes.

INVIMA practice is messy in public commentary. Some shops say the foreign manufacturer can remain titular if a Colombian representante legal is named; others sell themselves as the titular holder. Vexpro sells the second sentence. Either way, an in-country entity — and often a CCAA-licensed importer — appears on the record. INVIMA explicitly contemplates “un titular con varios importadores” on one registro sanitario. That is why an independent holder (or an independent legal representative plus a licensed importer that is not the exclusive distributor) is the structure that keeps the channel replaceable. See Colombia — INVIMA.

What Vexpro’s public holder line does not do: publish a 19-country own-entity subscription, include government fees and certified translations in one annual fee, or offer a trial-to-market bridge with a FIH CRO. They are a Colombia titular / BPO. Treat them as that.

Vexpro vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

bioaccess® still runs clinical trials in Colombia and treats commercial registro sanitario as a separate live service — not a substitute for the trial, and not something the trial team has to re-learn with a second vendor. Vexpro is a fair INVIMA titular for a Colombia-only commercial file. bioaccess® is the operator when Colombia is one market in a multi-country hold, or when the manufacturer already used bioaccess® as the FIH CRO.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

Search “consultoría regulatoria INVIMA dispositivos médicos” and DD9 Regulatorio is often the Spanish result that owns the page. That is a dossier and representation shop. It is not a clear “we are your titular holder” product. Sponsors who confuse SERP strength with holder structure end up with an excellent expediente and a distributor still named on the registro. This article states what dd9regulatorio.com actually publishes (retrieved 23 August 2026), without repeating manufacturer names from their site, and then points to the holder subscription from bioaccess®.

What DD9 publishes — and what it does not say

DD9 Regulatorio is a firm specialized exclusively in sanitary regulation of medical devices and IVD before INVIMA. Public metrics on the homepage (theirs): 10+ years; 43 companies accompanied; zero sanctions / zero “negaciones de fondo” on managed filings; 100+ records managed simultaneously; 1,700+ trámites; 350+ sanitary registrations in the firm’s history. They describe a five-stage method: diagnóstico, estrategia, ejecución, monitoreo (they brand a Control Tower), actualización.

Services they list: new registros, renewals, technical and legal modifications, responses to requerimientos, resolution corrections, CCAA certificates, manufacturer changes, importer changes, portfolio expansions, regulatory opinions, estándar semántico, tecnovigilancia, reactivovigilancia. Audiences: international manufacturers needing technical representation; importers and distributors with many records and different titulares; titulares needing maintenance; in-house RA teams; companies evaluating entry.

Read that list again. They work for titulares, importers, and manufacturers. They change importers and manufacturers on existing records. They do not say “actuamos como titular holder.” That is the distinction versus Vexpro’s homepage sentence and versus bioaccess®’s own-entity hold. DD9 can be the right INVIMA dossier counsel. Someone still has to be the named titular and, usually, a CCAA importer. If that someone is the exclusive distributor, the SERP win did not solve the leverage problem.

This page does not repeat client names that appear on DD9’s site. Company-published case anecdotes and success rates stay theirs.

What INVIMA actually requires for a commercial launch

Decreto 4725/2005: Class I and IIa receive registro sanitario automático (expedited issuance, verified post-hoc); Class IIb and III undergo full prior review on the order of ~90 business days. Foreign manufacturers need a Colombian legal face and typically a CCAA-licensed importer on the file. INVIMA allows one titular with several importers. Country page: Colombia INVIMA. IOR split: LATAM IOR.

DD9 vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

Keep DD9 in mind when the gap is an INVIMA expediente. Hire bioaccess® when the gap is who holds the license in Colombia and in the next four countries, and when that holder must not be the distributor.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

Argentina is a fused-holder market: the ANMAT Authorized Representative is typically the registration holder and the importer of record. Independent “hosting” shops that register under their own habilitaciones are the local analogue of a neutral titular. Budnik Regulatory Affairs publishes that product at bpregulatoryaffairs.com/hosting-productos-medicos (retrieved 23 August 2026). They are a fair one-country Argentina host. bioaccess® is the multi-country holder subscription that includes Argentina ANMAT among 19 markets.

What Budnik publishes

Hosting de Productos Médicos: they act as local representatives before ANMAT so national and international companies can register and import medical products in Argentina without their own habilitaciones. They say the model gives manufacturers a solid regulatory structure without requiring direct commercialization of the products — the manufacturer designs and manages its own local distribution network. They hold ANMAT habilitaciones that let them register under their titularidad different types and risk classes, assuming the corresponding sanitary responsibilities.

Cycle they list: regulatory strategy and viability; preparation, filing, and follow-up of the sanitary registration, including requirements, plus lifecycle maintenance; local sanitary representation; import support (authorizations, inbound traceability, coordination with warehouses, logistics operators, and manufacturer-designated distributors); tecnovigilancia (adverse events, authority interaction, feedback to the manufacturer). They invite class-and-type scoping by email on that page. This article does not invent a product-class list they did not publish.

Changing AAR in Argentina generally means re-registering. That is why the first holder choice is structural, not cosmetic. Foundational Disposición ANMAT N° 2318/2002 was abrogated and replaced by Disposición ANMAT N° 64/2025; the single-AAR-as-importer model remains the commercial fact sponsors plan around. Country page: Argentina — ANMAT.

Budnik vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

Budnik is a fair Argentina host when ANMAT is the only regulator on the plan. bioaccess® is the operator when the same family must also be held where holder and importer split (Mexico, Colombia, Brazil) and where they fuse (Argentina, El Salvador, Ecuador) — without hiring a new titular culture each time.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

DOMO Salute sells hospedagem de registros — Brazilian Registration Holder plus post-market work plus import authorizations (DDR) for named distributors. That is the Brazil product closest in shape to an independent holder who will also unlock the border. The public page is domosalute.com.br/pt/como-ajudamos/brazilian-registration-holder/ (retrieved 23 August 2026). This article names that offer fairly, then contrasts it with the multi-country LATAM Launch Subscription from bioaccess®.

What DOMO Salute publishes

They describe BRH as a fundamental step for international companies that want to regularize medical devices with ANVISA. As legal representative they assume responsibility for product regularization and ongoing compliance so manufacturers and local distributors can focus on commercial growth. As an independent BRH they advertise flexibility in choosing commercial partners and agility in managing records.

Four blocks on the hospedagem page:

• Local representation — technical and legal representative in Brazil; ANVISA regularizations.
• Post-market — complaints, adverse-event notifications, corrective actions.
• Renewals and regulatory updates — renewals, regularization updates, legislation monitoring, real-time alerts.
• Import authorizations and compliance — they issue import authorizations (DDR) for designated distributors and qualify those partners.

Related “Como Ajudamos” tiles: medical-device regularization including SaMD and IVD; hospedagem (they assume titularidade and sit between the international manufacturer and ANVISA); INMETRO & ANATEL certification support; BPF (good manufacturing practice) certification documentation for ANVISA.

They do not publish a 19-country holder subscription or government fees plus certified translations inside one annual LATAM fee. They are a Brazil hospedagem + DDR shop. That is a strong one-country product — especially versus a BRH that refuses to touch import.

Why DDR matters in Brazil

ANVISA names a single detentor de registro. That detentor can authorize multiple importadores without re-registering the device. Import letters / DDR are how a neutral holder lets several distributors land product without becoming the exclusive commercial channel. A manufacturer that gives the BRH role to Distributor A has to unwind that appointment to add Distributor B. A manufacturer that keeps an independent BRH (DOMO’s model, or bioaccess®’s Brazilian entity) adds and drops importadores on paper. Country page: Brazil ANVISA.

DOMO Salute vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

DOMO is a fair Brazil titular with import letters. bioaccess® is the operator when the same family must also be held in Mexico, Colombia, Argentina, Chile, or the rest of the published coverage — under one annual-fee shape, with the holder not used as leverage.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

Foreign manufacturers cannot hold an ANVISA medical-device registration in their own name. They appoint a Brazilian Registration Holder (BRH) — a local PJ authorized to represent the products. Sobel Consult publishes dedicated English and Portuguese pages for that role and is explicit about what it is not: importer or distributor. That is a clean one-country BRH. This article quotes their public product, then explains when the multi-country holder subscription from bioaccess® is the operator instead.

What Sobel Consult publishes

English: Brazilian Registration Holder for Medical Devices. Portuguese: representante legal no Brasil para dispositivos médicos (both retrieved 23 August 2026).

Public facts on the English BRH page:

• Audience: foreign manufacturers without a Brazilian legal entity that want to commercialize devices under ANVISA.
• Steps they describe: contract and designation letter appointing Sobel as BRH; recognition with ANVISA and communications; ongoing vigilance and regulatory updates; lifecycle support for as long as the manufacturer wants the device registered.
• Two modalities: BRH with INMETRO (electrical / electromedical in INMETRO scope) and BRH without INMETRO (ANVISA representation, vigilance, and distributor qualification only).
• Related services they list: notification / registration / updates under RDC 978/2025 and RDC 658/2022; INMETRO or ANATEL support; biological evaluation aligned with ISO 10993 and ANVISA.
• FAQ: a foreign manufacturer cannot hold its own Brazilian registration. Changing BRH later is possible if the regulatory updates are performed; they say their process is built for commercial independence so distributors can change without losing the registration. Sobel does not offer importation or distribution. QMS aligned with ISO 13485 and RDC 665 is expected of the manufacturer.

That last sentence is the important one. Brazil lets the detentor de registro authorize multiple importadores under one registration (RDC 270/2019; RDC 751/2022 names a single detentor). A BRH that refuses to import is a feature for manufacturers who want interchangeable distributors. It is also a gap if the sponsor expected one party to issue import letters and sit as IOR. See Brazil — ANVISA and the IOR guide.

Sobel Consult vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

Sobel is a fair Brazil-only BRH when the manufacturer already has — or will appoint — a separate importer. bioaccess® is the operator when Brazil is one country in a multi-market hold, when translations and government submission fees should sit inside the annual fee, and when the holder must not become commercial leverage.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

CAPIBAM’s entire public site is the independent Mexico Holder pitch. The homepage at capibammdr.com (retrieved 23 August 2026) says they act as Titular de Registro (Holder) for medical devices before COFEPRIS, independent of the distribution network. For a sponsor who only needs Mexico and only devices, that is a clean one-country product. This article states what they publish, then shows why bioaccess® is the multi-country holder subscription rather than another Mexico boutique.

What CAPIBAM publishes

CAPIBAM presents itself as a device-only sanitary-regulation shop. Public claims on the homepage:

• They lead “estrategia regulatoria y representación sanitaria” of medical devices in Mexico and act as Titular de Registro (Holder).
• Independence from the distribution network is the point: titularidad stays under the manufacturer’s control.
• Services: Class I–III registros, modifications, prórrogas, tecnovigilancia (including Informes Periódicos de Seguridad), and avisos / permisos de publicidad.
• More than 13 years of trajectory (their figure).
• Members of CAMEXA (Cámara Mexicano-Alemana de Comercio e Industria).
• They work with national and international manufacturers, distributors, and comercializadoras. Contact phone published: +52 (55) 7441 9286.

They do not publish a multi-country LATAM holder list, an all-in annual subscription with government fees and certified translations, or a clinical-to-commercial bridge. They are a Mexico device Holder. That is the product.

Independent holder is the right Mexico model — country is the constraint

The COFEPRIS rule is simple: the registration names a Mexican establishment. If that establishment is also the exclusive distributor, the manufacturer has outsourced both the license and the channel. CAPIBAM’s public wording is the correct commercial answer for Mexico-only: an independent titular, multiple channels, tecnovigilancia and publicity permits in the same shop. The constraint is geography. A U.S. or EU manufacturer that also needs ANVISA, INVIMA, ANMAT, ISP, or DIGEMID will otherwise hire a second titular, a third dossier vendor, and a fourth translator — and will rediscover that Argentina fuses holder and importer while Brazil lets the detentor authorize several importadores.

Country detail: Mexico COFEPRIS. Multi-importer vs single-IoR map: LATAM IOR.

CAPIBAM vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

CAPIBAM is a fair Mexico-only Holder. bioaccess® is the operator when the same device family must stay off the distributor’s license in more than one LATAM country.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

The URL regulate.com.mx/holder-mexico-cofepris is an exact-match page for “Mexico Registration Holder COFEPRIS.” REGULATE México is a homegrown shop that sells legal representation before COFEPRIS for foreign manufacturers that do not have a Mexican office. That is a legitimate one-country titular product. This page describes what REGULATE actually publishes, then contrasts it with the multi-country holder subscription from bioaccess®.

What REGULATE México publishes

The holder page (retrieved 23 August 2026) walks a three-step COFEPRIS path: (1) alta de establecimiento — aviso de funcionamiento and responsable sanitario for a Mexico-constituted company that will appear on the sanitary registration; (2) product notification / registro sanitario; (3) activity permits for import and publicity once the registro exists. For foreign firms it contrasts three models:

• Filial in Mexico — the manufacturer’s own titular. Advantages: control of timelines. Disadvantages they list: investment, time to constitute, a declared physical domicile, a quality system, and a farmaco / tecnovigilancia unit.
• Holder (“empresa estratégica”) — an establishment already notified to COFEPRIS, with a health professional as responsable sanitario and an existing farmaco / tecnovigilancia unit. They present this as avoiding the time to constitute a new Mexican company.
• Agreement with distributors — one or several distributors on the record. They list the usual risks: commission disputes, contracts written for the distributor, and confidentiality / industrial-design leakage.

FAQ facts they publish: they tell sponsors not to believe anyone who promises less than about 10 months after filing (they attribute current clocks to contingency backlog); sanitary registration validity is 5 years, then a prórroga; modifications include cesión de derechos, presentations, distributors, importers, and shelf life; as many distributors/importers as desired if each has its own aviso de funcionamiento. They say the work is done by RA specialists / pharmaceutical chemists who have worked inside COFEPRIS and/or Terceros Autorizados, and they claim review of around 500 expedientes with more than 95% success — those figures are theirs, not independently restated here as fact. They also work medicines, herbal remedies, cosmetics, supplements, non-alcoholic beverages, and foods. Devices are one of several product classes.

What that product is — and is not

REGULATE is a Mexico holder + dossier + import/publicity-permit shop. It is not a published 19-country subscription, not a holder that includes government fees and certified translations in one annual fee across LATAM, and not a trial-to-market CRO bridge. If Mexico is the only label, a homegrown “empresa estratégica” can be the right titular. If Mexico is one of five, the operating system matters more than the exact-match URL.

COFEPRIS allows multiple importers and distributors on one registration. That is why the independent-holder model they describe is useful. Details and the equivalence route: Mexico COFEPRIS.

REGULATE México vs bioaccess®

The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

When to use which

Use REGULATE when the search is literally “holder Mexico COFEPRIS,” the catalog may include non-device health products, and there is no second regulator on the launch plan. Use bioaccess® when the same device family must be held in Mexico and in other LATAM markets under one subscription, when certified translations and government submission fees should not appear as surprise line items, and when the same partner already ran — or will run — the first-in-human study.

If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.